Bennet Applauds Passage of Bipartisan FDA User Fees Reauthorization Bill
Bill Includes Bennet Measures to Support the Development of Innovative Cancer Drugs for Children, Enhance Clinical Trials, and Improve the Safety of Medical Devices
Aug 03, 2017
U.S. Senator Michael Bennet (D-CO) today applauded the passage of bipartisan legislation to reauthorize the Federal Drug Administration's (FDA) user fee programs for drugs and medical devices. The legislation includes three Bennet-led bills to support the development of innovative and promising cancer drugs for children, enhance clinical trials, and improve the safety of medical devices.